Global Health credit ratios

Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
1,1901,190328419842
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
59.859.8−794−756−436
0.30×0.30×0.10×0.14×0.35×
0.02×0.02×−0.23×−0.26×−0.18×
1.29×1.29×0.37×0.52×1.38×
0.06×0.07×−0.91×−0.95×−0.71×
8.80×8.80×10.47×8.47×5.93×
23.0%23.0%8.8%12.6%25.8%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

MEDANTA₹1,299.70

Global Health Ltd.

· Pharma & Health
₹ CrorePeersMAXHEALTHAPOLLOHOSPFORTISGLAXOANTHEMAJANTPHARMIPCALABABBOTINDIAMcap ₹34,922 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt842.2419.3327.91,190.01,190.0
Net Debt-435.9-755.9-794.559.859.8
Total Debt/Equity0.350.140.100.300.30
Net Debt/Equity-0.18-0.26-0.230.020.02
Total Debt/EBITDA1.380.520.371.291.29
Net Debt/EBITDA-0.71-0.95-0.910.070.06
Interest Coverage (EBIT/Interest)5.938.4710.478.808.80
Total Debt/Total Capital %25.7512.618.8223.0023.00
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.